Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VAL-1000 dose-escalation study in acute leukemias and high-risk MDS
ACTRN12612000970842Phase 2Withdrawn
- Sponsor
- Senz Oncology
- Start
- Oct 2012
- Countries
- 1
01
Overview
Phase 2, open-label trial of VAL-1000 in acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL) and myelodysplastic syndrome (MDS) (5 arms), sponsored by Senz Oncology. Primary endpoint: Safety and tolerability. Planned start Oct 2012; status: withdrawn.
02
Drugs
VAL-1000
03
Conditions
acute myeloid leukemia (AML)acute lymphoblastic leukemia (ALL)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ACTRN12612000970842.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12612000970842.